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Poster Session I S253interested in younger versus older patients(pts) for any difference in
disease characteristics and clinical outcome in the era of newer
agents.
Patients: We retrospectively analyzed 122 consecutive pts
(M77:F55) who underwent ASCT for multiple myeloma between
February, 2005 and July 2010, after newer agents were introduced.
Median age was 58 years (38-76). The median length of follow-up
was 1.1 year (33-1833days) after the initial transplant date.
Patient characteristics: High risk cytogenetics was seen in 40%
(n 5 29) of patients younger than 60 years of age compared to
28% (n5 14) of the pts in older group. Either deletion 13 or 17 de-
letion was similar in both groups 20% (n5 15) in younger and 22%
(n5 11) in older group. Trisomy 11 was more commonly seen in the
younger patients 11% (n 5 8) vs. 0%. Prior MGUS or smoldering
myeloma was more common in older pts (16%; n 5 8) vs. (7%;
n 5 5). Plasmacytomas (PCM) as presenting symptom was more
common 24% (n 5 17) in younger patients compared to 16%
(n 5 8) older pts.
Table 1. Patient characteristics of multiple myeloma patients
younger and older than 60 years of age
Age in years <60 (n572) >60 (n550)M:F 44 : 28 29 : 21
Disease prior to myeloma
Light chain disease 0 (0%) 2 (4%)
MGUS/smoldering MM 5 (7%) 8(16%)
Plasmacytoma 17 (24%) 8 (16%)
Amyloid 1 (1%) 3 (6%)
Plasma cell leukemia 0 (0%) 1 (2%)
De novo myeloma 49 (68%) 28 (56%)
WHO/ISS
albumin 3.6 (2.1-4.6) 3.6 (2.0-4.6)
Beta2 microglobulin 2.7 (1.4-34) 3.6 (1.3-15)
I 32 (44%) 12 (24%)
II 14 (19%) 22 (44%)
III 24 (33%) 12 (24%)
Not calculated 2(3%) 4 (8%)
Durie-Salmon staging
I 9 (12%) 9 (18%)
II 14 (19%) 17 (34%)
III 49 (68%) 24 (48%)
Cytogenetic abnormalities
13 del/17 del 15 (20%) 11 (22%)
Trisomy 11 8 (11%) 0 (0%)
T(11:14) 1 (1%) 3 (6%)
complex 5 (7%) 1 (2%)
aneuploidy 0 (0%) 1 (2%)
Pretransplant treatments
VAD/DVD 9 (12%) 9 (18%)
Melphalan 4 (7%) 4 (8%)
Thalidomide 18 (25%) 16 (32%)
Lenalidomide 14 (19%) 9 (18%)
Bortezomib 17 (24%) 12 (24%)
Post transplant treatments
Thalidomide 2 (3%) 2 (4%)
Lenalidomide 37 (51%) 29 (58%)
No maintenance 27 (38%) 18 (36%)
Second transplants 2 (3%) 1 (2%)Methods: Various pretransplant characteristics including cytoge-
netics and free light chain ratios were evaluated for remission status
and impact on progression.
Results: Majority of younger pts (44%; n 5 32) had stage I disease
by ISS staging compared to older pts with stage II disease (44%; n5
22). By Durie-Salmon staging majority had stage III disease; 68% of
younger (n5 49) compared to 48% of older pts (n5 24). The 3 year
overall survival was 71% for pts over 50 years of age compared to
40.2% for pts younger than 50 years of age (p5 0.065).Median sur-
vival was 927 days for patients younger than 50 years of age, but not
reached for pts older than 50 years. Three patterns of relapses were
seen: Bone marrow (BM) relapse; free light chains (FLC); plasmacy-toma only recurrence.None of the pts with FLC only relapse died of
relapse.
Conclusion:The younger patients have more aggressive clinical
presentation compared to older myeloma patients. Pre and post
transplant strategies need to be better defined to improve out-
come of younger myeloma patients with aggressive clinical
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COMBINED EPIGENETIC AND IMMUNE-BASED THERAPIES FOR RE-
LAPSED HODGKIN’S LYMPHOMA POST HEMATOPOIETIC STEM CELL
TRANSPLANT
Cruz, C.R.Y.1, Gerdemann, U.1, Shaffer, J.A.1, Leen, A.M.1,
Rooney, C.M.1, Younes, A.2, Horton, T.M.3, Heslop, H.E.1,
Bollard, C.M.1 1Baylor College ofMedicine/TheMethodist Hospital/Texas
Children’s Hospital, Houston, TX; 2Baylor College of Medicine, Houston,
TX; 3University of Texas MD Anderson Cancer Center, Houston, TX
Hematopoietic stem cell transplant (HSCT) remains the pri-
mary therapy for Hodgkin’s Lymphoma (HL) patients who re-
lapse following standard therapies. Those who relapse have
limited options for long-term cure. Two approaches have recently
shown promise: T cell therapy, and therapy with epigenetic-mod-
ifying drugs. As usually seen in cancer, a multimodality approach
may work best: we thus hypothesize that a combined immune–
based and epigenetic therapy, targeting our antigen of choice MA-
GEA4, will be an effective approach for treating relapsed HL post
HSCT.
Success in T cell therapy targeting Epstein Barr virus (EBV) pro-
teins in lymphoma is limited because most are EBV negative. MA-
GEA4 is expressed in EBV-negative HL, seen only in tumor &
immune-privileged germ cells, and immunogenic. We also observed
that we can increaseMAGE expression by epigenetic modification of
the tumor, supporting our hypothesis.
To verify whether MAGE T cells can be expanded from different
donors, cells from HL patients (n5 4), healthy donors (n5 15) and
cord blood (n 5 4) were stimulated weekly with autologous DCs
pulsed with MAGEA4 peptides. We generated a mixed population
of activated T cells with specificity against MAGE from all donor
types. These cells recognized different MAGE epitopes, and evalu-
able T cells demonstrated specific killing against autologous targets
and HLA-matched HL cell lines.
To explore the effect of combiningMAGET cells with the epige-
netic drug decitabine, we first looked at the effects of adding the drug
to our T cells – to ensure that the drug does not negatively affect
them. We saw no overt effects on or changes in phenotype or spec-
ificity when MAGEA4 T cells were cultured with decitabine. We
then confirmed that treatment of tumors with decitabine in vitro
increased MAGE expression using qPCR.
Lastly, we tested our prediction that increases in the frequency
of MAGEA4 specific T cells would be seen in HL patients receiv-
ing decitabine as therapy. We saw increased MAGEA4 specific T
cells in HL patients following treatment (likely reflecting increased
antigens in vivo) – manifested as an increase in the epitope reper-
toire and in the number of IFNg-secreting cells. We were unable
to expand MAGE T cells in all HL patients treated with decita-
bine, however, highlighting the need for adoptive transfer of these
cells.
These suggest that MAGEA4-specific T cell immunotherapy,
along with epigenetic therapy, is a practical approach for treatment
of relapsed HL post-HSCT.274
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Introduction: There is little information on the outcome of HIV1
pts with MM undergoing myeloablative chemotherapy with ASCT
Patients and Methods: 3 male HIV 1 pts with MM underwent
ASCT between June 2005 and December 2009. Median age of 46
years (43-66 years). All received multiagent chemotherapy including
bortezomib, dexamethasone, thalidomide, cisplatin, adriamycin, cy-
closphosphamise, etoposide (VDT-PACE) and granulocyte colony
stimulating factor (GCSF) for mobilization of hemopoeitic periph-
eral stem cells (HPC). HAART was held during VDT-PACE and
HPC. All collected adequate CD 341 cells/kg (median 25.4x106
cells/kg (17.4-31.9 x106 cells/kg)) for tandem transplant. HAART
was resumed during myeloablative chemotherapy and ASCT. De-
mographics, HIV viral load (VL), myeloma and HIV outcomes
were reviewed.
Results: Median absolute CD4 cell count prior to ASCT was 64
cells/mL (43-264 cells) and median HIV viral load (VL) was 2070
copies/mL (153-9550 copies/mL). Conditioning regimens were
melphalan 200 mg/m2 (2 pts) and carmustine, etoposide, adriamy-
cin, melphalan (BEAM, 1 pt). Median viable CD341 cells/kg in-
fused was 2.96  106/kg (range 2.58-3.26  106/kg). Median
days to neutrophil and platelet engraftment were respectively 11
(range 7-14) and 18 (range 16-19) days. Treatment-related compli-
cations included colitis (3 pts, C. difficile in 1), gram negative sepsis
(1 pt) and pulmonary aspergillosis (1 pt). Following ASCT, all pts
responded, with 2 achieving complete remission which was main-
tained for 1 year (1 pt) and 2 years (1 pt). One pt died 2 months
after transplant after refusing more treatment (cause of death un-
clear). The median CD4 count 1-3 months after transplantation
was 94 cells/uL (range 19-105) and median HIV VL was 1510 cop-
ies/mL (range 687-9270). The HIV VL was undetectable at 1 year
in 2 pts.
Conclusion:Myeloablative chemotherapy with ASCT can be safely
applied to HIV 1 pts with MM receiving HAART with good
outcome at 1-2 years after ASCT.275
AUTOLOGOUS STEM CELL TRANSPLANT (SCT) IN PATIENTS WITH
MULTIPLE MYELOMA (MM) OVER THE AGE OF 65 YEARS IS FEASIBLE
AND SAFE
Jagdeesh, D., Nath, R. UMassMemorial Medical Center,Worcester,MA;
Saint Vincent Medical Center, Worcester, MA
Background: Autologous SCT improves response rates and survival
in all newly diagnosed transplant eligible patients withMM. Patients
older than 65 years of age are frequently considered ineligible for this
procedure.
Materials and Methods: Retrospective analysis was performed on
all patients with MM over the age of 65 years who underwent au-
tologous SCT at UMass Memorial medical center since January
2003.
Results: 33 autologous SCT were performed on 27 patients with
MM over the age of 65 years. Thirteen (39%) SCT were performed
in patients older than 70 years. The median age at SCT was 68 years
(range 65-77).24 SCT were performed in males and 10 SCT were
performed in females.Myeloma subtype was IgG k 14 (52%); IgA
k 6 (22%); IgG l 4 (15%) and light chain myeloma in 3 (11%). Me-
dian time from diagnosis to transplant was 11 months (range 4-143).
In 13(48%) instances patients had more $ 3 therapies prior to their
SCT. 10(29%) of the SCT were 2nd transplants and there was one
instance of 3rd SCT. Preparative regimen was melphalan 100-
200mg/m2.Median time for neutrophil recovery was 11 days (range
9-12) and platelet recovery was 18 days (range 10-26). No patient
died within 100 days post transplant.1 year mortality was 10% (3/
31). The survival of patients $ 70 years was similar to those # 70
years. 7/15 (46%) of the patients transplanted beyond 5 years are still
alive.
Conclusion: Autologous SCT is feasible and a safe treatment mo-
dality for MM patients older than 65 years of age. This treatment
modality needs to be evaluated further in prospective randomized
clinical trials.276
CYTOGENETICS AND FLUORESCENCE IN SITU HYBRIDIZATION (FISH)
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Frahan, S., Mckinnon, R., Fortney, C., Janakiraman, N. Henry Ford
Hospital, Detroit, MI
Background: Multiple Myeloma (MM) has a very heterogeneous
prognosis. Many studies suggested that specific chromosomal
changes are of prognostic significance in patients with MM. Poor
risk include t(4;14), t(14;16),t(14;20), deletion p53, deletion 13 and
hypodiploidy. Changes of genetics during course of treatment and
outcome are not well studied. 132 cases of Multiple Myeloma trans-
plants were retrospectively reviewed from January 1st, 2000 to Au-
gust 1st, 2010. We looked at cytogenetics and fluorescence in situ
hybridization (FISH) before starting treatment, before and after
transplant.
Results: Out of 132 patients, 84.1% had Auto stem cell transplant
and 24 (15.9%) had Allo stem cell transplant. Mean age at diagnosis
was 54.6 (24-76). Patients with stage I-II were 28.2%, the rest had
stage III. 35 patients had monosomy or deletions of chromosome
13 (ch13) detected by FISH at diagnosis or any point during their
treatment. Of these, 11 patients had ch13 abnormality detected by
FISH during the course of treatment not at time of diagnosis. 3
(2.3%) patients had abnormalities of ch13 detected by cytogenetics.
11 patients had p53 deletion. It was detected in 8 patients before
transplant and was still detectable in 3 out of those 8 patients during
therapy and transplant. Another 3 patient had p53 deletion detected
only after transplant and was not detected before. 11 patients had
complex genetics at around time of diagnosis and 25 patients had
complex genetics detected just before and after time of transplant.
One patient had t(4;14). By time of analysis, there were 57 (43.2%)
death and 75 (56.8%) patients who were still alive. 80 (60.6%) pa-
tients had a relapse at one point. Median time to relapse (days) was
945 (251-9848). After dividing patients with high risk genetics at
any point during there treatment before or after transplant .and
standard risk, which includes everybody else, we found a significant
association between risk and death (p 5 0.001).
Conclusion: In this small group of 132 patients with MM who had
stem cell transplant in the last ten years from a single center we have
some data that may suggest high risk genetics detected at any point
during therapymay affect prognosis. This supports the need tomon-
itor genetics at diagnosis and during therapy. Since this is a small
group, further studies involving larger cohort of patients need to
be designed to confirm these results and study the effect of changes
of genetics during treatment of MM.277
SKELETAL CT SCAN IS MORE SENSITIVE THAN SKELETAL SURVEY
DURING THE PRE-TRANSPLANT EVALUATION FOR MULTIPLE MYELOMA
PATIENTS BUT HAS NO PROGNOSTIC SIGNIFICANCE
Moreb, J.S.1, Pettiford, L.1, Salejee, I.1, Bush, C.2 1University of Florida;
2University of Florida
Skeletal survey continues to be the gold standard radiologic
method for the detection of lytic lesions in multiple myeloma
(MM) patients. CT scans, MRI or PET scans have been used to eval-
uate specific symptoms. In our institution, we have used both skeletal
non-contrast CT scan and skeletal survey to evaluate for bone disease
during the pre-transplant evaluation of MM patients. Due to lack of
billing code for such test, the charges have been generated under the
code for CT scan of the abdomen or the spine. Our aim was to assess
the differences between the two modes of x-rays and to evaluate the
impact on progression –free (PFS) and overall survival (OS) after
stem cell transplant. We retrospectively reviewed the medical re-
cords of patients from our transplant registry that underwent stem
cell transplant (SCT) between January 2005 and December 2008.
Total of 154 patients were reviewed and 70 patients had the two
studies done during the pre-transplant evaluation. The following
data was collected: age, gender, stage of disease, albumin, b2-micro-
globulin, cytogenetics and FISH results, time to relapse, and time to
death. Patients were divided into two groups for comparison: those
who had differences between CT scan and skeletal survey findings
versus those who did not. The results show that CT scan had
more findings than the skeletal survey in 60% of the patients. These
